Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
WHO goals and milestones
Project details
Country
Angola, Azerbaijan, Bangladesh, Belarus, China, Congo D.R.C., DPR Korea, Ethiopia, India, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Mozambique, Myanmar, Nigeria, Pakistan, Papua New Guinea, Peru, Philippines, Republic of Moldova, Russia, Somalia, South Africa, Tajikistan, Thailand, Ukraine, Uzbekistan, Vietnam, Zimbabwe
